Deregulated expression of sprouty2 and microRNA-21 in human colon cancer: Correlation with the clinical stage of the disease

Cancer Biology and Therapy

Volumn 11, Issue 1, 2011, Pages 111-121

  Feng, Yin Hsun ^a,b,c   Wu, Chao Liang ^a   Tsao, Chao Jung ^b   Chang, Jan Gowth ^d   Lu, Pei Jung ^a   Yeh, Kun Tu ^e   Uen, Yih Huei ^b   Lee, Jeng Chang ^a   Shiau, Ai Li ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b CHI MEI MEDICAL CENTER   (Taiwan)

^c CHUNG HWA UNIVERSITY OF MEDICAL TECHNOLOGY   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

Author keywords

Cancer stage; Colon cancer; MicroRNA 21; Sprouty2; Tumor suppressor

Indexed keywords

MICRORNA 21; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; SPROUTY 2 PROTEIN; SPROUTY PROTEIN; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CARCINOGENESIS; CELL GROWTH; CELL MIGRATION; CLINICAL ASSESSMENT; CLINICAL FEATURE; COLON CANCER; DOWN REGULATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH;

ANIMALS; CELL GROWTH PROCESSES; COLONIC NEOPLASMS; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GENES, TUMOR SUPPRESSOR; HCT116 CELLS; HT29 CELLS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASM STAGING; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 78751498848     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.11.1.13965     Document Type: Article

References (47)

1. Tefft JD, Lee M, Smith S, Leinwand M, Zhao J, Bringas P Jr, et al. Conserved function of mSpry-2, a murine homolog of Drosophila sprouty, which negatively modulates respiratory organogenesis. Curr Biol 1999; 9:219-22.
2. Kim HJ, Bar-Sagi D. Modulation of signalling by Sprouty: a developing story. Nat Rev Mol Cell Biol 2004; 5:441-50.
3. Edwin F, Singh R, Endersby R, Baker SJ, Patel TB. The tumor suppressor PTEN is necessary for human Sprouty 2-mediated inhibition of cell proliferation. J Biol Chem 2006; 281:4816-22.
4. Egan JE, Hall AB, Yatsula BA, Bar-Sagi D. The bimodal regulation of epidermal growth factor signaling by human Sprouty proteins. Proc Natl Acad Sci USA 2002; 99:6041-6.
5. Feng YH, Tsao CJ, Wu CL, Chang JG, Lu PJ, Yeh KT, et al. Sprouty2 protein enhances the response to gefitinib through epidermal growth factor receptor in colon cancer cells. Cancer Sci 2010; 101:2033-8.
6. Lo TL, Yusoff P, Fong CW, Guo K, McCaw BJ, Phillips WA, et al. The ras/mitogen-activated protein kinase pathway inhibitor and likely tumor suppressor proteins, sprouty 1 and sprouty 2 are deregulated in breast cancer. Cancer Res 2004; 64:6127-36.
7. Fong CW, Chua MS, McKie AB, Ling SH, Mason V, Li R, et al. Sprouty 2, an inhibitor of mitogen-activated protein kinase signaling, is down-regulated in hepatocellular carcinoma. Cancer Res 2006; 66:2048-58.
8. Fritzsche S, Kenzelmann M, Hoffmann MJ, Muller M, Engers R, Grone HJ, et al. Concomitant downregulation of SPRY1 and SPRY2 in prostate carcinoma. Endocr Relat Cancer 2006; 13:839-49.
9. McKie AB, Douglas DA, Olijslagers S, Graham J, Omar MM, Heer R, et al. Epigenetic inactivation of the human sprouty2 (hSPRY2) homologue in prostate cancer. Oncogene 2005; 24:2166-74.
10. Slaby O, Svoboda M, Michalek J, Vyzula R. MicroRNAs in colorectal cancer: translation of molecular biology into clinical application. Mol Cancer 2009; 8:102.
11. Slaby O, Svoboda M, Fabian P, Smerdova T, Knoflickova D, Bednarikova M, et al. Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology 2007; 72:397-402.
12. Sayed D, Rane S, Lypowy J, He M, Chen IY, Vashistha H, et al. MicroRNA-21 targets Sprouty2 and promotes cellular outgrowths. Mol Biol Cell 2008; 19:3272-82.
13. Lee CC, Putnam AJ, Miranti CK, Gustafson M, Wang LM, Vande Woude GF, et al. Overexpression of sprouty 2 inhibits HGF/SF-mediated cell growth, invasion, migration and cytokinesis. Oncogene 2004; 23:5193-202.
14. Iqbal S, Lenz HJ. Integration of novel agents in the treatment of colorectal cancer. Cancer Chemother Pharmacol 2004; 54:32-9.
15. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-45.
16. Wells A. EGF receptor. Int J Biochem Cell Biol 1999; 31:637-43.
17. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003; 21:2787-99.
18. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19:183-232.
19. Yigzaw Y, Poppleton HM, Sreejayan N, Hassid A, Patel TB. Protein-tyrosine phosphatase-1B (PTP1B) mediates the anti-migratory actions of Sprouty. J Biol Chem 2003; 278:284-8.
20. Cummins JM, He Y, Leary RJ, Pagliarini R, Diaz LA Jr, Sjoblom T, et al. The colorectal microRNAome. Proc Natl Acad Sci USA 2006; 103:3687-92.
21. Krichevsky AM, Gabriely G. miR-21: a small multifaceted RNA. J Cell Mol Med 2009; 13:39-53.
22. Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. Jama 2008; 299:425-36.
23. Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, Post S, et al. MicroRNA-21 (miR- 21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2008; 27:2128-36.
24. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007; 133:647-58.
25. Zhu S, Si ML, Wu H, Mo YY. MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem 2007; 282:14328-36.
26. Wang P, Zou F, Zhang X, Li H, Dulak A, Tomko RJ Jr, et al. microRNA-21 negatively regulates Cdc25A and cell cycle progression in colon cancer cells. Cancer Res 2009; 69:8157-65
27. Gabriely G, Wurdinger T, Kesari S, Esau CC, Burchard J, Linsley PS, et al. MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. Mol Cell Biol 2008; 28:5369-80.
28. Sutterluty H, Mayer CE, Setinek U, Attems J, Ovtcharov S, Mikula M, et al. Downregulation of Sprouty2 in non-small cell lung cancer contributes to tumor malignancy via extracellular signal-regulated kinase pathway-dependent and -independent mechanisms. Mol Cancer Res 2007; 5:509-20.
29. Shaw AT, Meissner A, Dowdle JA, Crowley D, Magendantz M, Ouyang C, et al. Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis. Genes Dev 2007; 21:694-707.
30. Lito P, Mets BD, Kleff S, O'Reilly S, Maher VM, McCormick JJ. Evidence that sprouty 2 is necessary for sarcoma formation by HRAS oncogene transformed human fibroblasts. J Biol Chem 2008; 283:2002-9.
31. Ishida M, Ichihara M, Mii S, Jijiwa M, Asai N, Enomoto A, et al. Sprouty2 regulates growth and differentiation of human neuroblastoma cells through RET tyrosine kinase. Cancer Sci 2007; 98:815-21.
32. Frank MJ, Dawson DW, Bensinger SJ, Hong JS, Knosp WM, Xu L, et al. Expression of sprouty2 inhibits B-cell proliferation and is epigenetically silenced in mouse and human B-cell lymphomas. Blood 2009; 113:2478-87.
33. Yigzaw Y, Cartin L, Pierre S, Scholich K, Patel TB. The C terminus of sprouty is important for modulation of cellular migration and proliferation. J Biol Chem 2001; 276:22742-7.
34. Shim K, Minowada G, Coling DE, Martin GR. Sprouty2, a mouse deafness gene, regulates cell fate decisions in the auditory sensory epithelium by antagonizing FGF signaling. Dev Cell 2005; 8:553-64.
35. Taketomi T, Yoshiga D, Taniguchi K, Kobayashi T, Nonami A, Kato R, et al. Loss of mammalian Sprouty2 leads to enteric neuronal hyperplasia and esophageal achalasia. Nat Neurosci 2005; 8:855-7.
36. Taniguchi K, Sasaki K, Watari K, Yasukawa H, Imaizumi T, Ayada T, et al. Suppression of Sproutys has a therapeutic effect for a mouse model of ischemia by enhancing angiogenesis. PLoS One 2009; 4:5467.
37. Gross I, Bassit B, Benezra M, Licht JD. Mammalian sprouty proteins inhibit cell growth and differentiation by preventing ras activation. J Biol Chem 2001; 276:46460-8.
38. Poppleton HM, Edwin F, Jaggar L, Ray R, Johnson LR, Patel TB. Sprouty regulates cell migration by inhibiting the activation of Rac1 GTPase. Biochem Biophys Res Commun 2004; 323:98-103.
39. Miyoshi K, Wakioka T, Nishinakamura H, Kamio M, Yang L, Inoue M, et al. The Sprouty-related protein, Spred, inhibits cell motility, metastasis and Rho-mediated actin reorganization. Oncogene 2004; 23:5567-76.
40. Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, et al. Analysis of PTEN, BRAF and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 2009; 27:5924-30.
41. Loupakis F, Pollina L, Stasi I, Ruzzo A, Scartozzi M, Santini D, et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 2009; 27:2622-9.
42. Lito P, Mets BD, Appledorn DM, Maher VM, McCormick JJ. Sprouty 2 regulates DNA damageinduced apoptosis in Ras-transformed human fibroblasts. J Biol Chem 2009; 284:848-54.
43. Ding W, Warburton D. Downregulation of Sprouty2 via p38 MAPK plays a key role in the induction of cellular apoptosis by tumor necrosis factoralpha. Biochem Biophys Res Commun 2008; 375:460-4.
44. Yeh KT, Yang MY, Liu TC, Chen JC, Chan WL, Lin SF, et al. Abnormal expression of period 1 (PER1) in endometrial carcinoma. J Pathol 2005; 206:111-20.
45. Lee MH, Reynisdottir I, Massague J. Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev 1995; 9:639-49.
46. Salmon P, Trono D. Production and titration of lentiviral vectors. Curr Protoc Hum Genet 2007; 12:120.
47. Laronga C, Yang HY, Neal C, Lee MH. Association of the cyclin-dependent kinases and 14-3-3 sigma negatively regulates cell cycle progression. J Biol Chem 2000; 275:23106-12